{"id":"W2915708315","doi":"10.1200/jco.18.01998","title":"Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":398,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation","funders":"Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Nivolumab; Dosing; Oncology; Melanoma; Internal medicine; Metastatic melanoma; Clinical trial; Cancer; Immunotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008597998,0.0001018795,0.0008664901,0.0001011863,0.0000189594,0.000004982507,0.0001050727,0.0001471254,0.0000212295],"category_scores_gemma":[0.001602862,0.00005657599,0.0001413057,0.0001823373,0.000106638,0.0001400652,0.00001068106,0.0003723661,5.974147e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003780934,"about_ca_system_score_gemma":0.001351555,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001055433,"about_ca_topic_score_gemma":0.0005789916,"domain_scores_codex":[0.9964825,0.0006484829,0.001928018,0.0001746652,0.0006254528,0.0001408722],"domain_scores_gemma":[0.9945594,0.002060757,0.002342474,0.0001953825,0.0007939041,0.00004806863],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8177081,0.003783114,0.02089546,0.000007635762,0.0002271152,0.000004620863,0.0003333292,0.0001047699,0.000227563,0.000005107991,0.00008388896,0.1566193],"study_design_scores_gemma":[0.6930709,0.07319672,0.2310582,0.0003574982,0.0003261536,0.000003009608,0.0001577391,0.0008843997,0.0001229153,0.0001510905,0.0006123264,0.00005895577],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956155,0.0001561804,0.00003243078,0.001646485,0.0006459033,0.001673649,0.00001715937,0.000002332161,0.0002103603],"genre_scores_gemma":[0.9984789,0.00004839908,0.001036304,0.0002293332,0.000133692,0.00001325116,0.00003057864,0.00001171734,0.00001781088],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2101628,"threshold_uncertainty_score":0.2979912,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09565285910935743,"score_gpt":0.4600113664279852,"score_spread":0.3643585073186277,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}